the evolution of her2-low breast cancer from primary to recurrence
Published 1 year ago • 212 plays • Length 0:45Download video MP4
Download video MP3
Similar videos
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
2:09
the evolution of her2 targeting in metastatic breast breast cancer
-
1:09
the exciting new field of her2-low breast cancer
-
1:36
is her2-low a distinct subtype of breast cancer?
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
1:33
questions remaining in the field of her2-low breast cancer
-
0:56
remaining questions on the management of her2-low breast cancer
-
0:52
defining her2-low breast cancer as a clinical subtype
-
1:45
the comprehensive genomic characterization of her2-low breast cancer
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
6:51
adcs for her2 and her2-low breast cancer
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
0:31
remaining questions regarding her2-low breast cancer
-
0:35
key challenge associated with the management of hr /her2- breast cancer
-
2:30
destiny-breast04: t-dxd in her2-low breast cancer regardless of molecular markers
-
0:46
biological behaviour of her2-low bc is dependent on hr expression
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
0:32
highlights in her2-low breast cancer at sabcs 2022